Adefovir-dipivoxil

2021 ◽  
Vol 1881 (1) ◽  
pp. 19-19
Keyword(s):  
2010 ◽  
Vol 17 ◽  
pp. 66-72 ◽  
Author(s):  
L. J. Liu ◽  
J. H. Wang ◽  
S. C. Du ◽  
J. H. Tian ◽  
R. F. Yang ◽  
...  

2019 ◽  
Vol 566 ◽  
pp. 361-370 ◽  
Author(s):  
Kun Ma ◽  
Ningning Wang ◽  
Linfeng Cheng ◽  
Yuanfeng Wei ◽  
Jianjun Zhang ◽  
...  

2002 ◽  
Vol 37 (12) ◽  
pp. 1307-1317
Author(s):  
Dennis J. Cada ◽  
Terri Levien ◽  
Danial E. Baker

Each month, subscribers to The Formulary Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation (DUE) is also provided each month. The monographs are published in printed form and on diskettes that allow customization. Subscribers to the The Formulary Monograph Service also receive access to a pharmacy bulletin board, The Formulary Information Exchange (The F.I.X.). All topics pertinent to clinical and hospital pharmacy are discussed on The F.I.X. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. If you would like information about The Formulary Monograph Service or The F.I.X., call The Formulary at 800–322–4349. The November 2002 monograph topics are adefovir dipivoxil, ximelagatran, agalsidase alfa and agalsidase beta, pemetrexed, and emtricitabine. The DUE is on adefovir dipivoxil.


Sign in / Sign up

Export Citation Format

Share Document